Press Release - September 16th, 2024 SubjectWell Announces Strategic Acquisition of Trials24 to Expand Global Patient Recruitment Capabilities Austin, TX, September 17, 2024 — SubjectWell, provider of the most accurate, diverse, predictable, and patient-centric patient recruitment platform, is pleased to announce its acquisition of Trials24, a renowned provider of global digital patient recruitment solutions. This strategic acquisition will enhance SubjectWell’s ability to connect patients to transformative healthcare across all geographies. The integration of Trials24 into SubjectWell’s operations brings together two industry leaders who share a deep commitment to improving global healthcare. Trials24, with its cutting-edge technology, digital marketing expertise, and engagement center with local native language representatives in more than 13 European countries, joins forces with SubjectWell’s Patient Network of over 13 million patients interested in pursuing new treatments, including 6 million people of color. With an innovative solution to patient engagement, retention and fulfillment, SubjectWell is the only partner capable of delivering excellence in global patient recruitment. “This acquisition is an exciting new chapter for SubjectWell,” said Fred Martin, Chief Executive Officer of SubjectWell. “By combining our strengths with those of Trials24, we are poised to set a new standard in patient recruitment. Together, we will expand our global reach, drive diversity in clinical trials, and offer unparalleled technology suite and services to our clients. More importantly, we will improve access to clinical trials for patients everywhere, ushering in a new era of effective and inclusive clinical research.” “We are thrilled to join forces with SubjectWell,” said Dr. Tobias Kruse, “Chief Executive Officer of Trials24. “Our shared vision of improving patient access to clinical trials aligns perfectly, and we are excited about the opportunities this new chapter presents. Together, we will have the largest reach of patients and engagement centers to support all global studies.” SubjectWell and Trials24 have already begun integrating their businesses. The transition will not impact any customer or patient engagements. About SubjectWell SubjectWell provides the most accurate, diverse, predictable, and patient-centric platform that connects patients and caregivers to breakthrough healthcare opportunities that transform lives. With a Patient Network of 13 million+ patients interested in pursuing new treatments, including over 6 million people of color, combined with innovative patient engagement and retention strategies, SubjectWell has helped sponsors, Clinical Research Organizations (CROs), clinical sites, and site networks connect thousands of patients to clinical studies across all therapeutic areas. For more information, visit www.subjectwell.com. Contact: Suzanne Harris Suzanne.harris@subjectwell.com (512) 354-2343
Austin, TX, September 17, 2024 — SubjectWell, provider of the most accurate, diverse, predictable, and patient-centric patient recruitment platform, is pleased to announce its acquisition of Trials24, a renowned provider of global digital patient recruitment solutions. This strategic acquisition will enhance SubjectWell’s ability to connect patients to transformative healthcare across all geographies. The integration of Trials24 into SubjectWell’s operations brings together two industry leaders who share a deep commitment to improving global healthcare. Trials24, with its cutting-edge technology, digital marketing expertise, and engagement center with local native language representatives in more than 13 European countries, joins forces with SubjectWell’s Patient Network of over 13 million patients interested in pursuing new treatments, including 6 million people of color. With an innovative solution to patient engagement, retention and fulfillment, SubjectWell is the only partner capable of delivering excellence in global patient recruitment. “This acquisition is an exciting new chapter for SubjectWell,” said Fred Martin, Chief Executive Officer of SubjectWell. “By combining our strengths with those of Trials24, we are poised to set a new standard in patient recruitment. Together, we will expand our global reach, drive diversity in clinical trials, and offer unparalleled technology suite and services to our clients. More importantly, we will improve access to clinical trials for patients everywhere, ushering in a new era of effective and inclusive clinical research.” “We are thrilled to join forces with SubjectWell,” said Dr. Tobias Kruse, “Chief Executive Officer of Trials24. “Our shared vision of improving patient access to clinical trials aligns perfectly, and we are excited about the opportunities this new chapter presents. Together, we will have the largest reach of patients and engagement centers to support all global studies.” SubjectWell and Trials24 have already begun integrating their businesses. The transition will not impact any customer or patient engagements. About SubjectWell SubjectWell provides the most accurate, diverse, predictable, and patient-centric platform that connects patients and caregivers to breakthrough healthcare opportunities that transform lives. With a Patient Network of 13 million+ patients interested in pursuing new treatments, including over 6 million people of color, combined with innovative patient engagement and retention strategies, SubjectWell has helped sponsors, Clinical Research Organizations (CROs), clinical sites, and site networks connect thousands of patients to clinical studies across all therapeutic areas. For more information, visit www.subjectwell.com. Contact: Suzanne Harris Suzanne.harris@subjectwell.com (512) 354-2343
